Last reviewed · How we verify

Trivalent Influenza Vaccine intradermal dose

Seqirus · Phase 1 active Biologic

Trivalent Influenza Vaccine intradermal dose is a Biologic drug developed by Seqirus. It is currently in Phase 1 development.

At a glance

Generic nameTrivalent Influenza Vaccine intradermal dose
SponsorSeqirus
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Trivalent Influenza Vaccine intradermal dose

What is Trivalent Influenza Vaccine intradermal dose?

Trivalent Influenza Vaccine intradermal dose is a Biologic drug developed by Seqirus.

Who makes Trivalent Influenza Vaccine intradermal dose?

Trivalent Influenza Vaccine intradermal dose is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What development phase is Trivalent Influenza Vaccine intradermal dose in?

Trivalent Influenza Vaccine intradermal dose is in Phase 1.

Related